GRANALIX is a biotechnology start-up company, founded by Professor Ruth Gabizon – senior researcher from the Department of Neurology at Hadassah University Hospital, Jerusalem – together with Professor Shlomo Magdassi, an international expert in the field of Nanotechnology from the Casali Center, Institute of Chemistry, at the Hebrew University of Jerusalem.
The development of GranaGard is a product of their joint activities and their extensive knowledge acquired over the years in various fields of research. GRANALIX was founded as a subsidiary of “Yissum”, the technology transfer company of the Hebrew University, and Hadasit, the technology transfer company of Hadassah Medical Center.
Professor Ruth Gabizon
Professor Ruth Gabizon is a researcher at Hadassah University Hospital in Jerusalem. Prof. Gabizon completed a post-doctorate at the University of California, San Francisco (UCSF) with Professor Stanley Prusiner. Prof. Prusiner is an American Neurologist and Biochemist who discovered a class of pathogens that he named prions; pathological proteins with disease-transmission capacity – for which he received the Nobel Prize in Physiology and Medicine in 1997. In 1988, Prof. Gabizon returned to Israel and continued her research at Hadassah University Hospital.
Professor Shlomo Magdassi
Professor Shlomo Magdassi is a Professor of Chemistry at the Casali Center for Applied Chemistry at the Hebrew University of Jerusalem. The research group led by Prof. Magdassi focuses on materials science and nanotechnology. Professor Magdassi has published over 220 academic articles and several groundbreaking developments. He is considered a global expert in the field of nanomaterials creation and application.
Our website uses cookies to provide you the best experience. However, by continuing to use our website, you agree to our use of cookies. For more information, read our Cookie Policy.